SELLAS Life Sciences Group (NASDAQ:SLS) Hits New 1-Year High - Still a Buy?

SELLAS Life Sciences Group logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • SELLAS shares surged to a new 52-week high, reaching $27.05 intraday and last trading at $23.44, versus a prior close of $7.47; trading was unusually volatile and temporarily paused.
  • The company plans to discuss an accelerated FDA filing strategy for its investigational GPS therapy and is preparing for a potential BLA submission in the first half of 2027. GPS was generally well tolerated with no new safety signals, but the FDA has not agreed to a filing or accelerated pathway, and further analysis could affect the results.
  • Analyst views are mixed: two analysts rate the stock Buy and one Sell, for a consensus Hold and a $10 average price target—well below the latest trading price.
  • Five stocks we like better than SELLAS Life Sciences Group.

Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) reached a new 52-week high during mid-day trading on Tuesday. The company traded as high as $27.05 and last traded at $23.4350, with a volume of 20,998,041 shares changing hands. The stock had previously closed at $7.47.

Key Headlines Impacting SELLAS Life Sciences Group

Here are a few of the latest headlines about SLS:

  • Positive Sentiment: The company plans to discuss an accelerated filing strategy with the FDA and is preparing for a Biologics License Application submission in the first half of 2027. GPS was generally well tolerated, with no new safety signals reported. GPS trial results and planned FDA filing
  • Neutral Sentiment: Trading in SLS was temporarily paused for news and later for a Limit Up-Limit Down (LULD) pause, indicating unusually volatile trading around the announcement.
  • Negative Sentiment: GPS remains investigational. The FDA has not agreed to a filing or accelerated path, and final analyses could affect the interpretation of the topline results; the trial focused on a specific, high-risk AML patient group.

Analyst Upgrades and Downgrades

SLS has been the topic of several research analyst reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of SELLAS Life Sciences Group in a research note on Thursday, October 15th. Alliance Global Partners reiterated a "buy" rating on shares of SELLAS Life Sciences Group in a report on Wednesday, August 12th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $10.00.

Read Our Latest Research Report on SLS

SELLAS Life Sciences Group Price Performance

The stock has a 50-day moving average price of $10.90 and a 200-day moving average price of $8.79. The firm has a market capitalization of $3.68 billion, a PE ratio of -88.28 and a beta of 2.73.

SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last issued its quarterly earnings results on Thursday, November 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.05).

Institutional Investors Weigh In On SELLAS Life Sciences Group

Several institutional investors and hedge funds have recently made changes to their positions in the company. Bank of America Corp DE lifted its stake in SELLAS Life Sciences Group by 535.7% in the first quarter. Bank of America Corp DE now owns 641,683 shares of the company's stock valued at $2,714,000 after buying an additional 540,748 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in shares of SELLAS Life Sciences Group during the second quarter valued at $7,823,000. Goldman Sachs Group Inc. grew its holdings in shares of SELLAS Life Sciences Group by 86.0% during the third quarter. Goldman Sachs Group Inc. now owns 1,088,136 shares of the company's stock valued at $13,395,000 after buying an additional 503,101 shares in the last quarter. Marshall Wace LLP acquired a new position in SELLAS Life Sciences Group during the third quarter valued at $3,494,000. Finally, Wellington Management Group LLP raised its position in SELLAS Life Sciences Group by 73.2% during the second quarter. Wellington Management Group LLP now owns 597,309 shares of the company's stock valued at $8,816,000 after buying an additional 252,531 shares during the period. 17.38% of the stock is owned by institutional investors and hedge funds.

SELLAS Life Sciences Group Company Profile

(Get Free Report)

SELLAS Life Sciences Group is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its research centers on immunotherapies and other therapies intended to address hematologic malignancies and solid tumors. The company does not have an established portfolio of marketed products; its work is focused on clinical development. Its pipeline includes galinpepimut-S (GPS), an immunotherapy designed to target the Wilms' tumor 1 (WT1) protein, which is found in several types of cancer.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in SELLAS Life Sciences Group Right Now?

Before you consider SELLAS Life Sciences Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SELLAS Life Sciences Group wasn't on the list.

While SELLAS Life Sciences Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines